{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:55:53Z","timestamp":1789232153430,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance &amp;lt;30mL\/min or requiring renal replacement therapy). Few studies have evaluated RDV in patients with SRI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Hospitalized patients who received RDV between 1 May 2020 and 31 October 2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality, and length of stay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of a total of 135 patients, 20 had SRI. Patients with SRI were significantly older (70 vs 54 years, P\u2005=\u2005.0001). The incidence of possible AEs was 30% among those with SRI vs 11% without (P\u2005=\u2005.06). Liver function test (LFT) elevations occurred in 10% vs 4% (P\u2005=\u2005.28), and serum creatinine (SCr) elevations in 27% vs 6% (P\u2005=\u2005.02) of patients with SRI vs without, respectively. LFT and SCr elevations were not attributed to RDV in either group.<\/jats:p><jats:p>Mortality and length of stay were consistent with historical controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>RDV AEs occurred infrequently and overall were not significantly different between those with and without SRI. While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury prior to RDV. The use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity. Additional studies are needed to confirm this finding.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa1851","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T03:38:19Z","timestamp":1607571499000},"page":"e3990-e3995","source":"Crossref","is-referenced-by-count":46,"title":["Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-8039","authenticated-orcid":false,"given":"Natasha N","family":"Pettit","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pisano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison K","family":"Lew","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renslow","family":"Sherer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Mullane","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"2021121022392209000_CIT0001","author":"COVID-19 Treatment Guidelines Panel"},{"key":"2021121022392209000_CIT0002","first-page":"NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19\u2014final report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121022392209000_CIT0003","volume-title":"Remdesivir (Veklury\u00ae) prescribing information","year":"2020"},{"key":"2021121022392209000_CIT0004","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/jps.22109","article-title":"Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)","volume":"99","author":"Luke","year":"2010","journal-title":"J Pharm Sci"},{"key":"2021121022392209000_CIT0005","article-title":"Safety of remdesivir in patients with acute or chronic kidney disease. Kidney Int Rep","author":"Thakare","year":"2020"},{"key":"2021121022392209000_CIT0006","first-page":"dkaa500","article-title":"Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis","author":"S\u00f6rgel","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021121022392209000_CIT0007","first-page":"e25616","article-title":"Cancer, transplantation, and other immunocompromising conditions were not significantly associated with severe COVID-19 or death in hospitalized COVID-19 patients in Chicago","volume":"23","author":"Sherer","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2021121022392209000_CIT0008","first-page":"ASN.2020050615","article-title":"AKI in hospitalized patients with COVID-19","author":"Chan","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2021121022392209000_CIT0009","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3390\/jcm9082506","article-title":"COVID-19 and the kidney: from epidemiology to clinical practice","volume":"9","author":"Gagliardi","year":"2020","journal-title":"J Clin Med"},{"key":"2021121022392209000_CIT0010","doi-asserted-by":"crossref","DOI":"10.1136\/jim-2020-001407","article-title":"Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis","author":"Hansrivijit","year":"2020","journal-title":"J Investig Med"},{"key":"2021121022392209000_CIT0011","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1056\/NEJMc2015312","article-title":"Compassionate use of remdesivir in Covid-19","volume":"382","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121022392209000_CIT0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14218\/JCTH.2020.00018","article-title":"COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies","volume":"8","author":"Feng","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"2021121022392209000_CIT0013","doi-asserted-by":"crossref","first-page":"e1003406","DOI":"10.1371\/journal.pmed.1003406","article-title":"Acute kidney injury associated with COVID-19: a retrospective cohort study","volume":"17","author":"Kolhe","year":"2020","journal-title":"PLoS Med"},{"key":"2021121022392209000_CIT0014","first-page":"1","article-title":"CKD is a key risk factor for COVID-19 mortality","author":"Gansevoort","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2021121022392209000_CIT0015","first-page":"S0085-2538(20)30945-5","article-title":"Outcomes of patients with end-stage kidney disease hospitalized with COVID-19","author":"Ng","year":"2020","journal-title":"Kidney Int"},{"key":"2021121022392209000_CIT0016","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1128\/AAC.05841-11","article-title":"Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia","volume":"56","author":"Oude Lashof","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121022392209000_CIT0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2334-13-14","article-title":"Evaluation of intravenous voriconazole in patients with compromised renal function","volume":"13","author":"Lilly","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2021121022392209000_CIT0018","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/myc.12517","article-title":"Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether \u03b2-cyclodextrin in haematological patients with renal impairment","volume":"59","author":"Kim","year":"2016","journal-title":"Mycoses"},{"key":"2021121022392209000_CIT0019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-015-0753-8","article-title":"Evaluation of sulfobutylether-\u03b2-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy","volume":"19","author":"Kiser","year":"2015","journal-title":"Crit Care"},{"key":"2021121022392209000_CIT0020","volume-title":"Voriconazole (VFend\u00ae) prescribing information","year":"2010"},{"key":"2021121022392209000_CIT0021","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1681\/ASN.2020050589","article-title":"Remdesivir in patients with acute or chronic kidney disease and COVID-19","volume":"31","author":"Adamsick","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2021121022392209000_CIT0022","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/phar.2429","article-title":"Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2021121022392209000_CIT0023","first-page":"NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"key":"2021121022392209000_CIT0024","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1851\/36198487\/ciaa1851.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3990\/41608150\/ciaa1851.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3990\/41608150\/ciaa1851.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T20:14:39Z","timestamp":1670098479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e3990\/6033734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,12,14]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1851","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,12,14]]}}}